AbCellera Biologics Inc.
ABCL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $2 | $3 | $4 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $2 | $3 | $4 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -24.2% | -92.2% | 29.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 86.3% | 87.9% |
| EBITDA | -$0 | -$0 | $0 | $0 |
| % Margin | -708% | -505.3% | 53.6% | 63.7% |
| Net Income | -$0 | -$0 | $0 | $0 |
| % Margin | -564.8% | -385% | 32.7% | 40.9% |
| EPS Diluted | -0.55 | -0.51 | 0.5 | 0.48 |
| % Growth | -7.8% | -202% | 4.2% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | $0 | $0 |